Moderna and Merck Present Cancer Vaccine Trial Results; Shares React
The latest in this situation
- Moderna presented individualized neoantigen therapy data at ESMO, alongside analyst notes.
- Moderna's therapy combined with Merck's drug in an Australian-led clinical trial.
- Merck and Moderna funded an Australian-led clinical trial involving the University of Sydney.
- Moderna completed a successful Phase III mRNA vaccine trial with MSD and Geneva University Hospitals.
How it started
What happened
Moderna and Merck presented data on their individualized neoantigen therapy, intismeran autogene, at the European Society for Medical Oncology meeting. The Phase 3 trial, which included 1,137 high-risk melanoma patients, showed that combining the vaccine with Merck's Keytruda reduced the risk of melanoma death or recurrence by 42%. Despite these findings, Moderna's shares sold off by double digits, and Merck's stock fell about 1.8% following the results.
From biopharmadive.com, independent.co.uk, scientificamerican.com
Why it matters
The results demonstrate that pairing a custom mRNA vaccine with an immune-boosting drug can successfully halt disease progression in melanoma. However, investor uncertainty remains regarding the vaccine's effectiveness against other tumor types and the commercial viability of its personalized manufacturing process.
Who's involved
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.How it developed
Newest first. Tap a step to see who reported it.Moderna presented individualized neoantigen therapy data at ESMO, alongside analyst notes.1 source
- Moderna and Merck are seeking FDA review for a novel cancer treatment, having co-led a Phase 3 mRNA vaccine trial.Sub-event
- Moderna and Merck are developing a combination therapy using Keytruda.Sub-event
Moderna and Merck are advancing personalized cancer treatment research and seeking regulatory approval for new drug trials.1 source
Moderna partners with Merck on cancer vaccines and seeks FDA approval for flu vaccine.1 source
Keep exploring
The entities involved
Related events
Coverage
Newest first; wire copies grouped- fool.com
- biopharmadive.com
- independent.co.uk
- scientificamerican.com
- themarketsdaily.com
- medicaldaily.com
- biopharmadive.com
- aol.com
- cnbc.com
- koaa.com
- dailyadvance.com
- fool.com
40 more outlets ran the same wire story
- hindustantimes.com
- bostonherald.com
- spokesman.com
- fool.com
- dailypolitical.com
- ksl.com
- wenxuecity.com
- ibtimes.com
- wenxuecity.com
- financial-news.co.uk
- fool.com
- themarketsdaily.com
- themarketsdaily.com
- insidermonkey.com
- yahoo.com
- fortune.com
- insidermonkey.com
- yahoo.com
- cnbcafrica.com
- livemint.com
- cbsnews.com
- ibtimes.com
- hindustantimes.com
- irishtimes.com
- scmp.com
- kmbc.com
- chicagotribune.com
- ibtimes.co.uk
- yahoo.com
- businessinsider.com
- fool.com
- kcci.com
- gulfcoastnewsnow.com
- financialcontent.com
- yahoo.com
- proactiveinvestors.com
- artvoice.com
- bostonglobe.com
- kcci.com
- ynetnews.com